Bassan R, Barbui T
Divisione di Ematologia, Ospedali Riuniti, Bergamo, Italy.
Haematologica. 1995 Jan-Feb;80(1):82-90.
The primary goal of acute myeloid leukemia chemotherapy is to obtain a complete remission. In adults with de novo disease, response rates reach between sixty and seventy per cent with classical '3 + 7' or DAT schemes. Curative postinduction treatments are now available for responsive patients, which makes it mandatory to look for more effective modalities of induction therapy. Experience gathered in recent years shows that idarubicin, cytosine arabinoside, and etoposide together might contribute to the modeling of an improved remission induction regimen: ICE. Because ICE and similar programs are being used with increasing frequency worldwide, we decided to review critically the underlying issues and the evidence supporting this change.
急性髓系白血病化疗的主要目标是实现完全缓解。在初发疾病的成人患者中，采用经典的“3 + 7”或DAT方案时，缓解率可达60%至70%。目前已有针对反应性患者的根治性诱导后治疗方法，这使得必须寻找更有效的诱导治疗方式。近年来积累的经验表明，去甲柔红霉素、阿糖胞苷和依托泊苷联合使用可能有助于构建一种改进的缓解诱导方案：ICE。由于ICE及类似方案在全球范围内的使用频率越来越高，我们决定严格审查相关的基本问题以及支持这一变化的证据。
